Stories about Debiopharm's
-
Language:
English
- Media:
- Period:
- Period:Total
- more
NUCLEAI SECURED $6.5M SERIES-A INITIAL CLOSING LED BY DEBIOPHARM TO ADVANCE AI-POWERED PRECISION ONCOLOGY PLATFORM
moreDebiopharm's Novel Microbiome Remodeling Program Licensed to Takeda for the Treatment of Gastrointestinal Disorders
moreFDA grants Breakthrough Therapy Designation for Debiopharm's novel chemo-radio sensitizer Debio 1143 for front-line treatment of Head & Neck Cancer
moreKnight Partners with Debiopharm for the Commercialization of Trelstar® in Canada
moreDebiopharm's novel IAP antagonist Debio 1143 achieves outstanding Phase II results for high-risk Head and Neck cancer patients
moreDebiopharm and BIOASTER join forces to expand research to combat infectious diseases
more
1